Short-term Dual Antiplatelet Therapy Not Safe in Patients With Acute Coronary Syndrome

Heart attack risk increases with short-term dual antiplatelet therapy in patients with acute coronary syndrome.

The largest trial to date concludes that short-term dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) cannot be deemed safe. ACS patients who were given DAPT for only six months had more than double the risk of a heart attack compared with those treated for at least 12 months, according to research presented at the American College of Cardiology's 67th Annual Scientific Session.

Also, the combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients who were randomly assigned to receive dual antiplatelet therapy for either six months or at least 12 months after receiving a drug-eluting stent.

Aspirin/Clopidogrel Drug Reduces Bleeding Risk Post-Acute Coronary Syndrome Treatment
Bleeding risk reduced in acute coronary syndrome patients when switched to aspirin/clopidogrel following treatment with new P2Y12 inhibitors like prasugrel.

‘Clinical trial findings suggest that the current guidelines that recommend prolonged DAPT in patients with ACS should continue to be followed.’

"Based on our findings, we can't say that short-term DAPT is safe in patients with ACS who have received drug-eluting stents," said Hyeon Cheol Gwon, MD, a professor in the Division of Cardiology at Sungkyunkwan University, director of the cardiac center at Samsung Medical Center in Seoul, South Korea, and principal investigator of the study. "We conclude that current guidelines that recommend prolonged DAPT in patients with ACS who are not at excessive risk for bleeding should continue to be followed."

Acute coronary syndrome Acute coronary syndrome occurs when blood flow to the heart is suddenly blocked. It may take the form of a heart attack or unstable angina, chest pain that may signal an imminent heart attack. Patients who have had one episode of ACS are at elevated risk for another. ACS is often treated by inserting a small metal tube, or stent, into a blocked artery to keep the artery open, a procedure known as an angioplasty. A drug-eluting stent is a stent that has been coated with a drug to prevent scar tissue from forming inside the artery.

Current guidelines published by the American College of Cardiology and the American Heart Association recommend that ACS patients not at excessive risk for bleeding should be treated with DAPT-- aspirin plus clopidogrel or a similar drug such as ticagrelor--for at least 12 months after the implantation of a drug-eluting stent.

Physicians Underestimate Acute Coronary Syndrome Risk in Women and Minorities
Gender and racial disparities persist in the emergency department when it comes to the evaluation of chest pain with the potential for acute coronary syndrome.

However, there is limited evidence that 12 months or more is the optimal duration for DAPT, Gwon said. Two recently reported studies suggested that six months of DAPT might offer similar benefits in terms of reducing patients' risk for death, heart attack or stroke, bleeding or other adverse events. These studies, however, had too few participants to provide definitive answers, he said.

"This is the largest trial to address the optimal duration of DAPT in patients with ACS," Gwon said.

Young Women With Acute Coronary Syndrome Do As Well As Men
The rate of death among young to middle-aged adults has increased due to increasing prevalence of abdominal obesity, diabetes, and hypertension.

The SMART-DATE trial enrolled a total of 2,712 Korean patients with ACS who were undergoing angioplasty. Their median age was 63 years, and 75 percent were male. Patients were randomly assigned to receive either DAPT for at least 12 months (DAPT-12) or DAPT for six months followed by aspirin alone for at least another six months (DAPT-6). The primary endpoint was the combined rate of death from any cause, heart attack or stroke within 18 months after stent insertion.

At 18 months, 63 patients (4.7 percent) in the DAPT-6 group and 56 patients (4.2 percent) in the DAPT-12 group had experienced at least one of the primary endpoint events. Thus, over the entire 18-month follow-up period, DAPT-6 was significantly not worse (or non-inferior) than DAPT-12, Gwon said. Rates of death from any cause were not significantly different in the two groups (2.6 percent in the DAPT-6 group vs 2.9 percent in the DAPT-12 group).

People Adhere To Medication Better After Being Hospitalized For Acute Coronary Syndrome
A study finds that patients better adhered to their medication regimens in the year following hospitalization for acute coronary syndrome (ACS).

However, the risk of heart attack was 2.4-fold higher in the DAPT-6 group, with heart attacks occurring in 1.8 percent of DAPT-6 patients vs. 0.8 percent of DAPT-12 patients. Moreover, during the period between six and 18 months after stent insertion when patients in the DAPT-6 group were being treated with aspirin only, there was a 5.1-fold risk of having a heart attack in DAPT-6 patients compared with DAPT-12 patients. During this period, patients in the DAPT-6 group also had a 69 percent higher risk of dying from any cause or having a heart attack or stroke.

Limitations of the study, Gwon said, include the absence of blinding-- that is, both patients and doctors knew whether a patient was in the DAPT-6 or the DAPT-12 group--and the absence of a group that was randomly assigned to receive a placebo. However, study statisticians and those whose role was to assess outcomes worked independently from those overseeing the trial, he said.

Patients in the trial will be followed for an additional 18 months, for a total of three years of follow-up, Gwon said.

Source-Eurekalert